Therapeutic Potential of Black Pepper Compound for BRaf Resistant Melanoma

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Phenformin enhances the therapeutic benefit of BRAF inhibition in melanoma

Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129; Institute for Cancer Genetics and Departments of Dermatology and Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032; Department of Dermatology, Yale University School of Medicine, New Haven, CT 06520; Helen Diller Family Comprehensive Cancer Center...

متن کامل

BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.

Selective BRAF inhibitors (BRAFi) yield objective responses in 50% of patients with metastatic BRAF V600E mutant melanoma. Adding an MEK inhibitor increases this response rate to 70%. Limited data are available on the outcomes of unresectable stage III patients, and it remains unclear whether BRAF-targeted therapy can be utilized as a neoadjuvant strategy. Data on patients with advanced locoreg...

متن کامل

Dabrafenib for treatment of BRAF-mutant melanoma

Melanoma has the highest mortality of all the skin cancer subtypes. Historically, chemotherapy and immunologic therapies have yielded only modest results in the treatment of metastatic melanoma. The discovery of prevalent V600 BRAF mutations driving proliferation makes this oncogenic protein an ideal target for therapy. Dabrafenib, a reversible inhibitor of mutant BRAF kinase, improved response...

متن کامل

Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.

Targeted therapies are increasingly being used to treat a variety of cancers. Their efficacy depends upon the accurate detection and targeting of a specific mutation or aberration in the tumor. All cancers, such as melanoma, are molecularly heterogeneous, with drug-resistant subclones present before the treatment or emerging as a result of targeted therapies. Here, we show intralesional molecul...

متن کامل

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma

Melanoma is one of the most aggressive cancers in the world and is responsible for the majority of skin cancer deaths. Recent advances in the field of immunotherapy using active, adoptive, and antigen-specific therapeutic approaches, have generated the expectation that these technologies have the potential to improve the treatment of advanced malignancies, including melanoma. Treatment options ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Proceedings

سال: 2017

ISSN: 2504-3900

DOI: 10.3390/proceedings1100981